Radnor Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.87M | Sell |
77,621
-869
| -1% | -$22.7K | 0.26% | 101 |
|
|
2026
Q1 | $2.2M | Hold |
78,490
| – | – | 0.33% | 80 |
|
|
2025
Q4 | $1.95M | Sell |
78,490
-7,007
| -8% | -$177K | 0.29% | 97 |
|
|
2025
Q3 | $2.18M | Hold |
85,497
| – | – | 0.33% | 83 |
|
|
2025
Q2 | $2.07M | Sell |
85,497
-200
| -0.2% | -$4.66K | 0.33% | 81 |
|
|
2025
Q1 | $2.17M | Hold |
85,697
| – | – | 0.36% | 69 |
|
|
2024
Q4 | $2.27M | Sell |
85,697
-17,005
| -17% | -$461K | 0.38% | 71 |
|
|
2024
Q3 | $2.97M | Buy |
+102,702
| New | +$3M | 0.44% | 57 |
|
|
2024
Q2 | – | Sell |
-86,007
| Closed | -$2.39M | – | 263 |
|
|
2024
Q1 | $2.39M | Sell |
86,007
-2,865
| -3% | -$79.5K | 0.41% | 56 |
|
|
2023
Q4 | $2.56M | Buy |
88,872
+11,635
| +15% | +$352K | 0.48% | 48 |
|
|
2023
Q3 | $2.56M | Buy |
+77,237
| New | +$2.73M | 0.51% | 41 |
|
|
2023
Q2 | – | Sell |
-58,971
| Closed | -$2.41M | – | 216 |
|
|
2023
Q1 | $2.41M | Buy |
58,971
+9,054
| +18% | +$391K | 0.63% | 33 |
|
|
2022
Q4 | $2.65M | Buy |
49,917
+1,817
| +4% | +$87.1K | 0.65% | 32 |
|
|
2022
Q3 | $2.1M | Sell |
48,100
-1,700
| -3% | -$82.6K | 0.61% | 37 |
|
|
2022
Q2 | $2.61M | Buy |
49,800
+3,800
| +8% | +$194K | 0.71% | 29 |
|
|
2022
Q1 | $2.38M | Sell |
46,000
-368
| -0.8% | -$19.1K | 0.6% | 43 |
|
|
2021
Q4 | $2.74M | Buy |
+46,368
| New | +$2.3M | 0.68% | 33 |
|
|
2021
Q3 | – | Sell |
-51,298
| Closed | -$2.01M | – | 179 |
|
|
2021
Q2 | $2.01M | Hold |
51,298
| – | – | 0.68% | 34 |
|
|
2021
Q1 | $1.86M | Hold |
51,298
| – | – | 0.6% | 45 |
|
|
2020
Q4 | $1.89M | Sell |
51,298
-2,770
| -5% | -$102K | 0.53% | 41 |
|
|
2020
Q3 | $1.88M | Buy |
54,068
+4,741
| +10% | +$166K | 0.63% | 37 |
|
|
2020
Q2 | $1.58M | Buy |
49,327
+2,635
| +6% | +$89.5K | 0.57% | 39 |
|
|
2020
Q1 | $1.45M | Sell |
46,692
-5,777
| -11% | -$197K | 0.59% | 39 |
|
|
2019
Q4 | $1.95M | Sell |
52,469
-2,424
| -4% | -$86.3K | 0.6% | 37 |
|
|
2019
Q3 | $1.87M | Buy |
54,893
+843
| +2% | +$30.7K | 0.61% | 38 |
|
|
2019
Q2 | $2.22M | Sell |
54,050
-2,980
| -5% | -$118K | 0.73% | 28 |
|
|
2019
Q1 | $2.3M | Buy |
57,030
+1,265
| +2% | +$50.7K | 0.75% | 28 |
|
|
2018
Q4 | $2.31M | Buy |
55,765
+136
| +0.2% | +$5.65K | 0.83% | 22 |
|
|
2018
Q3 | $2.33M | Buy |
55,629
+432
| +0.8% | +$16.6K | 0.74% | 29 |
|
|
2018
Q2 | $1.9M | Buy |
55,197
+211
| +0.4% | +$7.21K | 0.7% | 36 |
|
|
2018
Q1 | $1.85M | Sell |
54,986
-536
| -1% | -$18.4K | 0.63% | 39 |
|
|
2017
Q4 | $1.91M | Buy |
55,522
+1,371
| +3% | +$46.7K | 0.61% | 40 |
|
|
2017
Q3 | $1.73M | Hold |
54,151
| – | – | 0.58% | 39 |
|
|
2017
Q2 | $1.73M | Hold |
54,151
| – | – | 0.58% | 39 |
|
|
2017
Q1 | $1.76M | Sell |
54,151
-2,424
| -4% | -$76.4K | 0.59% | 38 |
|
|
2016
Q4 | $1.74M | Buy |
+56,575
| New | +$1.73M | 0.6% | 38 |
|
Other funds holding PFE
Radnor Capital Management's PFE Position: Q2 2026 in Review
Radnor Capital Management reduced its Pfizer (PFE) stake by 1.1% in Q2 2026, selling an estimated $22.7K and leaving 77,621 shares worth $1.87M. The position accounts for 0.26% of the portfolio, ranked #101.
Radnor Capital Management first reported a position in PFE in Q4 2016 and has held it in 36 quarters since. The position peaked at $2.97M in Q3 2024. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Radnor Capital Management held 77,621 shares of Pfizer worth $1.87M as of Q2 2026.
- Radnor Capital Management sold 869 Pfizer shares in Q2 2026, an estimated $22.7K.
- Pfizer made up 0.26% of Radnor Capital Management's portfolio in Q2 2026, its #101 holding.
- Radnor Capital Management first reported a position in Pfizer in Q4 2016 and has held it in 36 quarters since.
- Radnor Capital Management's Pfizer position peaked at $2.97M in Q3 2024.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Radnor Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.